CR 14629
Alternative Names: CR-14629Latest Information Update: 26 Aug 2021
Price :
$50 *
At a glance
- Originator Rottapharm Biotech
- Class Antirheumatics
- Mechanism of Action Adipokine modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Osteoarthritis
Most Recent Events
- 26 Aug 2021 CR 14629 is available for licensing as of 26 Aug 2021. https://www.rottapharmbiotech.com/pipeline/
- 19 Sep 2019 Early research in Osteoarthritis in Italy (unspecified route)